Publications & Research
This publication presents one of the earliest peer-reviewed frameworks examining the economic implications of pharmacogenetic testing. Co-authored by Brian Meshkin and colleagues at Prometheus Laboratories, the paper explores how pharmacogenetics can improve healthcare outcomes while reducing overall treatment costs, helping establish the field of pharmacogenomic health economics.
View on PubMed →Building upon his work developing foundational pharmacogenetic assays for antifolate therapies, Brian Meshkin explores the relationship between dietary folate metabolism, nutritional genetics, and folic acid supplementation. The publication highlights the growing intersection between pharmacogenetics and personalized nutrition.
View on PubMed →This publication examines the complex genetic basis of ADHD, proposing that the disorder is highly polygenic and influenced by numerous genes involved in neurotransmitter metabolism, transport, and receptor function. The paper challenged conventional views of ADHD and contributed to the understanding of its biological foundations.
View on PubMed →Researchers from Proove evaluated the impact of incorporating genetic testing into the management of chronic pain. The study demonstrated how genetic information could assist clinicians in developing more individualized treatment strategies for patients experiencing chronic non-cancer pain.
View on PubMed →This validation study evaluated the Proove Opioid Risk algorithm, which integrates genetic and clinical variables to estimate an individual's risk for opioid use disorder. The publication provides evidence supporting the algorithm's application within precision medicine and opioid risk assessment.
View on PubMed →This clinical case report describes the application of precision medicine in the treatment of a patient experiencing unresolved pain following orthopedic surgery. The report highlights how genetic testing informed clinical decision-making and personalized pain management.
View on PubMed →This prospective clinical study evaluated the real-world utility of the proprietary Proove predictive algorithm for opioid use disorder risk stratification. The findings support the use of integrated genetic and clinical data to improve individualized patient risk assessment.
View on PubMed →This publication outlines how pharmacogenetic testing can be incorporated into evidence-based treatment guidelines for injured workers suffering from chronic pain. The recommendations contributed to the broader discussion surrounding precision medicine in workers' compensation and informed later updates to clinical practice guidelines.
View on PubMed →This study evaluated the performance of the Proove Opioid Risk algorithm in an addiction treatment setting. The researchers reported strong predictive performance, supporting the algorithm's application for identifying individuals at elevated risk of opioid misuse within clinical addiction medicine.
View Publication →